Asset Dedication’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$886 Hold
3
– – ﹤0.01% 1078
2026
Q2
$681 Sell
3
-88
-97% -$15.7K ﹤0.01% 1137
2026
Q1
$15.7K Hold
91
– – ﹤0.01% 679
2025
Q4
$18.2K Hold
91
– – ﹤0.01% 678
2025
Q3
$14.2K Sell
91
-13
-13% -$2.06K ﹤0.01% 738
2025
Q2
$15.8K Buy
104
+13
+14% +$1.73K ﹤0.01% 742
2025
Q1
$13.7K Hold
91
– – ﹤0.01% 717
2024
Q4
$16.8K Hold
91
– – ﹤0.01% 687
2024
Q3
$17.9K Hold
91
– – ﹤0.01% 710
2024
Q2
$18.8K Hold
91
– – ﹤0.01% 693
2024
Q1
$25K Hold
91
– – ﹤0.01% 543
2023
Q4
$22K Hold
91
– – ﹤0.01% 553
2023
Q3
$18K Buy
91
+3
+3% +$616 ﹤0.01% 585
2023
Q2
$19K Hold
88
– – ﹤0.01% 564
2023
Q1
$18K Hold
88
– – ﹤0.01% 570
2022
Q4
$19K Buy
+88
New +$19.2K ﹤0.01% 557
2021
Q4
– Sell
-9
Closed -$4K – 945
2021
Q3
$4K Buy
+9
New +$3.74K ﹤0.01% 812

Other funds holding CRL

Asset Dedication's CRL Position: Q3 2026 in Review

Asset Dedication held its Charles River Laboratories (CRL) position steady in Q3 2026 at 3 shares worth $886. The position accounts for ﹤0.01% of the portfolio, ranked #1078.

Asset Dedication first reported a position in CRL in Q3 2021 and has held it in 17 quarters since. The position peaked at $25K in Q1 2024. 515 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

  • Asset Dedication held 3 shares of Charles River Laboratories worth $886 as of Q3 2026.
  • Asset Dedication left its Charles River Laboratories share count unchanged in Q3 2026.
  • Charles River Laboratories made up ﹤0.01% of Asset Dedication's portfolio in Q3 2026, its #1078 holding.
  • Asset Dedication first reported a position in Charles River Laboratories in Q3 2021 and has held it in 17 quarters since.
  • Asset Dedication's Charles River Laboratories position peaked at $25K in Q1 2024.
  • 515 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Asset Dedication's 13F filing for Q3 2026, filed 3 Nov 2026.